Yahoo Finance • 10 months ago
In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stock... Full story
Yahoo Finance • last year
— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Webcast Today at 8:00 AM ET — WAYNE, Pa... Full story
Yahoo Finance • last year
Aclaris Therapeutics Inc (NASDAQ:ACRS) reported Q3 2023 financial results with total revenue of $9.28 million. The company's cash, cash equivalents and marketable securities as of September 30, 2023, were $187.0 million, down from $229.8 m... Full story
Yahoo Finance • last year
- Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced; Topline Data Anticipated Around Year-End 202... Full story
Yahoo Finance • last year
- Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-infla... Full story
Yahoo Finance • last year
WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that membe... Full story
Yahoo Finance • last year
– Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases – WAYNE, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceut... Full story
Yahoo Finance • last year
In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout. If you want to skip out on an introduction to small cap stocks and the latest events in the stock market, then take a look at 5 Cheap Small-Ca... Full story
Yahoo Finance • last year
Biotech investors like it when one of their companies reports gains in a developmental program, and that was the dynamic behind Tuesday's rise in the share price of Aclaris Therapeutics (NASDAQ: ACRS). The trial will take the form of a ran... Full story
Yahoo Finance • last year
- Topline Data Anticipated in Q4 2023 WAYNE, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammator... Full story
Yahoo Finance • 2 years ago
WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will repo... Full story
Yahoo Finance • 2 years ago
WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that membe... Full story
Yahoo Finance • 2 years ago
Recent Philadelphia-area life sciences includes Aclaris and Incyte suffering setbacks with experimental therapies. Continue reading... Full story
Yahoo Finance • 2 years ago
- Study Did Not Meet Primary or Secondary Efficacy Endpoints in Hidradenitis Suppurativa - Overall Safety Profile and PK/PD Generally Consistent with Observations in Prior Studies of Zunsemetinib WAYNE, Pa., March 06, 2023 (GLOBE NEWSWI... Full story
Yahoo Finance • 2 years ago
WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financi... Full story
Yahoo Finance • 2 years ago
WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that member... Full story
Yahoo Finance • 2 years ago
WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today is providing a corpor... Full story
Yahoo Finance • 2 years ago
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Ped... Full story
Yahoo Finance • 2 years ago
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appo... Full story
Yahoo Finance • 2 years ago
WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the co... Full story